10207 Results

People

  1. Gonen
    Gonen
  2. Vickers
    Vickers
  3. Panageas
    Panageas
  4. Patil
    Patil
  5. Schultz
    Schultz
  6. Giralt
    Giralt
  7. Zhang
    Zhang
  8. Jarnagin
    Jarnagin
  9. Heller
    Heller
  10. D'Angelica
    D'Angelica

Groups

  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)
  7. Solid Tumor Oncology Division (3294)
  8. GSK Faculty (2807)
  9. Center for Pancreatic Cancer Research (2495)
  10. Health Outcomes Research Group (2069)
  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (6429)
  2. Meeting Abstract (3245)
  3. Editorial (116)
  4. Review (93)
  5. Research Letter (80)
  6. Correspondence (77)
  7. Conference Paper (54)
  8. Miscellaneous (52)
  9. Book Section (43)
  10. Guidelines (13)
  11. Book Whole (5)
Groups
  1. Epidemiology and Biostatistics (10207)
  2. Biostatistics Service (6564)
  3. Department of Medicine (4907)
  4. Population Sciences Research Program (4867)
  5. Surgery (3680)
  6. Survivorship Research (3597)

More Groups

People
  1. Mithat Gonen (1028)
  2. Andrew Vickers (880)
  3. Sean Devlin (601)
  4. Katherine Panageas (512)
  5. Sujata Patil (511)
  6. Nikolaus Schultz (486)

More People

Years
  1. 2025 (209)
  2. 2024 (622)
  3. 2023 (692)
  4. 2022 (732)
  5. 2021 (610)
  6. 2020 (625)

More Years

Publications
  1. Journal of Clinical Oncology (1374)
  2. Blood (534)
  3. Annals of Surgical Oncology (462)
  4. Cancer Research (274)
  5. International Journal of Radiation Oncology, Biology, Physics (258)
  6. Clinical Cancer Research (250)

More Publications

Publishers
  1. American Society of Clinical Oncology (1487)
  2. Elsevier Inc. (1206)
  3. Springer (925)
  4. American Association for Cancer Research (761)
  5. Elsevier Science, Inc. (685)
  6. American Society of Hematology (601)

More Publishers

Results (10207)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling
    Meeting Abstract

    Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Nath, K.; Lee, J.; Elko, T. A.; Levy, L.; Preston, E.; Devlin, S. M.; Ponce, D. M.; Lin, R. J.; Shaffer, B. C.; Cho, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
    Meeting Abstract

    Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial treatment response is prognostic and predictive of relapse patterns: Outcomes of >500 patients treated for primary CNS lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; Cederquist, G. Y.; Vachha, B.; Schaff, L.; Hajj, C.; Hubbeling, H.; Zhang, Z.; White, C.; more...
    Blood (2022)

    Fulltext@MSK | Save